Dr Anthony Fauci, the director of the US National Institute of Allergy and Infectious Diseases (NIAID), has said that three doses of the COVID-19 vaccine are likely to be needed for full protection, CNN reported on Friday.
Dr Fauci cited two Israeli studies that showed a decrease in infections among people who got a third or booster shot. He added that there was good reason to believe that a third dose "will actually be durable, and if it is durable, then you're going to have very likely a three-dose regimen being the routine regimen."
The US Food and Drug Administration (FDA) will consider whether to approve a third dose later this month.
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
ALK partners with GenSci to expand allergy immunotherapy market in China
Ionis publishes positive Phase 3 data supporting donidalorsen as HAE prophylactic
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Alvotech reports positive topline results for Xolair biosimilar study
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
Celltrion's OMLYCLO receives US FDA approval
Kenox Pharmaceuticals partners with Lactiga US
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy